Abstract
Objective
To evaluate the efficacy and safety of nedaplatin/gemcitabine (NG) and carboplatin/gemcitabine (CG) in the management of untreated advanced non-small cell lung cancer (NSCLC).
Methods
Sixty-two patients with previously untreated advanced NSCLC were recruited between June 2006 and November 2007. Subjects were randomly assigned to the NG arm (n=30) and the CG arm (n=32). Only patients (24 and 25 in the NG and CG arms, respectively) who completed ≥2 chemotherapy cycles were included in the data analysis. The primary outcome measure was the objective response rate (ORR). The secondary outcome measures included progression-free survival (PFS), overall survival (OS) and adverse events.
Results
There were no statistically significant differences in the efficacy measures (ORR, P=0.305; median PFS, P=0.198; median OS, P=0.961) or in the major adverse events (grade 3/4 neutropenia, P=0.666; grade 3/4 anemia, P=0.263; grade 3/4 thrombocytopenia, P=0.212) between the two treatment arms. However, there was a trend towards higher ORR (37.5% vs. 24.0%), longer PFS (6.0 vs. 5.0 months), and less adverse events in the NG arm.
Conclusion
NG regimen seems to be superior over CG regimen for advance NSCLS, but further investigation is needed to validate this superiority.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wagner TD, Yang GY. The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curr Drug Targets 2010; 11:67–73.
Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Williston Park) 2004; 18:21–26.
Maione P, Rossi A, Bareschino MA, et al. “Factors driving the choice of the best second-line treatment of advanced NSCLC.” Rev Recent Clin Trials 2011; 6:44–51.
Belvedere O, Grossi F. Lung Cancer Highlights from ASCO 2005. Oncologist 2006; 11:39–50.
Rinaldi M, Cauchi C, Gridelli C, et al. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006; 17:64–67.
Kameyama Y, Okazaki N, Nakagawa M, et al. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 1990; 52:15–24.
Ota K, Wakui A, Majima H, et al. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho (in Japanese) 1992; 19:855–861.
Kurata T, Tamura K, Yamamoto N, et al. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 2004; 90:2092–2096.
Shirai T, Hirose T, Noda M, et al. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 2006; 52:181–187.
Fukuda M, Shinkai T, Eguchi K, et al. Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990; 26:393–396.
Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC). Gan To Kagaku Ryoho (in Japanese) 1992; 19:1019–1026.
Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23:8380–8388.
Ramalingam S, Belani CP. Carboplatin/gemcitabine combination in advanced NSCLC. Oncology (Williston Park) 2004; 18(8 Suppl 5):21–26.
Matsumoto M, Takeda Y, Naki H, et al. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res 2001; 92:51–58.
Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710–1717.
Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Brit J Radiol 2001; 74:983–986.
Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0, DCTD, NCI, NIH, DHHS. August 9, 2006. http://ctep.cancer.gov/forms/ CTCAEv3.pdf. Accessed July 16, 2007.
Hirose T, Horichi N, Chmori T, et al. Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 2003; 39:91–97.
Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with Gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007; 2:430–439.
Nakajima O, Inoue S, Kobayashi K. Differences in intracellular uptake of cisplatin, carboplatin and 254-S among human lung cancer cell lines. Japan J Lung Cancer 1994; 34:313–319.
Naito Y, Kubota K, Ohmatsu H, et al. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Ann Oncol 2011; 781:1–5.
Oshita F, Honda T, Murakami S, et al. Comparison of nedaplatin and irinotecan for patients with squamous and non-squamous cell carcinoma of the lung: meta-analysis of four trials. J Thorac Oncol 2011; 6:128–131.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, Jj., Zhou, Q., Liao, Rq. et al. Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial. Chin. J. Cancer Res. 24, 97–102 (2012). https://doi.org/10.1007/s11670-012-0097-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11670-012-0097-8